Dublin, OH (May 19, 2014) – The addition of Dr. He adds leadership and natural products drug discovery experience to Biosortia’s Science Team. Dr. He has more than 20 years of experience in pharmaceutical R&D, specializing in the discovery of drug leads from natural products and their semi-synthetic analogs in oncology, infectious disease, and other therapeutic areas. Haiyin worked as a principal scientist III and group leader at Wyeth Research and after the merger between Pfizer and Wyeth, he continued on to work at Pfizer World Wide Medicinal Chemistry as an associate research fellow in the area of antibody-drug conjugates for cancer chemotherapy. Haiyin received a doctorate in marine natural products at Scripps Institution of Oceanography with John Faulkner, and then acquired a postdoctoral experience at Chemistry Department, Cornell University with Jon Clardy.

###

About Biosortia Pharmaceuticals – Biosortia Pharmaceuticals is a division of Algaeventure Systems (AVS). Biosortia has a proven and unique ability to obtain unculturable aquatic microorganism consortia from the natural environment in unprecedented quantities that allows its research team to perform a direct study of vast quantities of new natural products. Biosortia is actively engaging drug research and development organizations to explore the vast opportunity of unculturable microorganisms for potential therapeutic agents, and other novel compounds of value in biotechnology fields.